Drug intelligence / Profile preview

IDE

Development stage: Preclinical
Lead developer: Adaxion Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

IDE is a preclinical-stage recombinant IgG-degrading enzyme (protease) being developed by Adaxion Therapeutics for the treatment of IgG-driven disorders. Engineered using Adaxion's proprietary ADAx platform, which incorporates CD22 ligands to eliminate drug-specific B cells and reduce immunogenicity, IDE is designed to proteolytically cleave and degrade pathogenic IgG antibodies. This rapid enzymatic cleavage eliminates Fc-mediated effector functions and transiently reduces circulating IgG levels, offering a potential therapeutic approach for various autoimmune and IgG-mediated diseases with reduced risk of anti-drug antibody (ADA) formation.

Other names: IgG-degrading enzyme

Beyond the preview

Go deeper on IDE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDE.

Explore the full profile